Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction. "CSPS"


Phase 3 Results

Summary of Purpose

The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral infarction in patients who had suffered a cerebral infarction 1 to 6 months prior to entering the trial.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 8 January 2009.

1 Apr 1992 2 Oct 2008 1 Mar 1997 1 Mar 1997 1 Jan 2009 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Fumio Gotoh, MD, 35 Shinano-machi, Shinjuku-ku, Tokyo, Japan.